12,220 trials (keyword fallback)
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
Head and Neck Neoplasms · Pheochromocytoma · Colorectal Neoplasms
Primary: Response Rate — 0; 0; 26; 11 Participants
Non-small Cell Lung Cancer · Lung Cancer
Primary: Progression-Free Survival (PFS) in the Overall Population — 17.3; 14 Weeks
Cystic Fibrosis
Primary: Feasibility of Participants Completing 2-week Study Visit — 25; 25; 0 Participants
Acute Respiratory Distress Syndrome · Acute Lung Injury
Primary: Oxygenation — 10 Participants
Extensive Stage Small Cell Lung Carcinoma · Large Cell Lung Carcinoma · Neuroendocrine Carcinoma
Primary: Recommended Phase II Dose (Phase I) — 100 mg
Non-Small Cell Lung Cancer
Primary: Duration of Treatment of Anti-cancer Drugs — 11; 14; 9.4; 15.8 Months
Multiple Sclerosis
Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants
Urothelial Carcinoma · Urothelial Cancer · Lung Neoplasms
Primary: Phase I: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of EP0057 (CLRX101) in Participants With Refractory Cancers. — 12 mg/m^2
Recurrent Lung Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8 · Stage IVA Lung Cancer AJCC v8
Primary: Overall Survival (OS) — 11.6; 14.5 months — p=0.05
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 1.8; 1.3; 1.4; 1.4 Months
Video-assisted Thoracoscopic Surgery · Lung Isolation Device · One-lung Ventilation
Primary: Time to Obtain Complete Lung Collapse — 47.8; 32.5 minutes
Advanced Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8
Primary: Objective Response Rate (ORR) — 2 percentage of participants
Bronchiolitis Obliterans · Constructive Bronchiolitis · Graft Versus Host Disease
Primary: Improvement in Lung Function - Increase in FEV1 — 0 Participants
Constrictive Bronchiolitis · Bronchiolitis Obliterans · Graft vs Host Disease
Primary: Overall Response to Treatment Based on Positive Response to Cyclosporine Inhalation Solution (CIS) — 9; 0 Participants